<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）的股票在周一由 Oppenheimer 的研究分析师在一份发给客户和投资者的研究报告中重申了 “市场表现” 评级，Benzinga 报道。他们目前对该股票的目标价为 58.00 美元。Oppenheimer 的目标价意味着该股票当前价格有 9.63% 的潜在上涨空间。</p>
<p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
<p>其他一些分析师也最近对 TERN 发表了评论。BMO 资本市场在 3 月 26 日的研究报告中将 Terns Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。华尔街 Zen 在 3 月 21 日的报告中将 Terns Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。瑞穗证券在 3 月 27 日的报告中对 Terns Pharmaceuticals 的股票设定了 53.00 美元的目标价。威廉·布莱尔在 4 月 7 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，巴克莱在 3 月 30 日的报告中重申了 “等权重” 评级，并对 Terns Pharmaceuticals 的股票设定了 53.00 美元的目标价（低于 56.00 美元）。一位投资分析师对该股票给予了强力买入评级，三位给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 55.14 美元。</p>
<p><strong>查看我们对 Terns Pharmaceuticals 的最新股票分析</strong></p>
<h2>Terns Pharmaceuticals 股票表现</h2>
<p>周一中午交易时，TERN 的股票上涨 0.02 美元，达到 52.91 美元。该公司的交易量为 747,846 股，而其平均交易量为 4,899,822 股。该公司的 50 日移动平均价格为 47.82 美元，200 日移动平均价格为 35.70 美元。Terns Pharmaceuticals 的 52 周最低价为 2.65 美元，52 周最高价为 53.19 美元。该公司的市值为 61.1 亿美元，市盈率为-51.36，贝塔值为-0.37。</p>
<p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最近在 3 月 30 日发布了季度财报。该公司报告每股收益（EPS）为-0.24 美元，超出分析师的共识预期（-0.30 美元）0.06 美元。整体来看，研究分析师预测 Terns Pharmaceuticals 在当前财政年度将发布-1.07 的每股收益。</p>
<h2>内部人士下注</h2>
<p>在其他 Terns Pharmaceuticals 的新闻中，内部人士 Emil Kuriakose 在 4 月 1 日的交易中出售了 942 股该公司的股票。这些股票的平均售价为 52.75 美元，总交易额为 49,690.50 美元。交易完成后，该内部人士直接持有 105,673 股公司股票，价值约为 5,574,250.75 美元。此次交易使其持股减少了 0.88%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席执行官 Amy L. Burroughs 在 3 月 16 日的交易中出售了 14,583 股该公司的股票。这些股票的平均售价为 46.71 美元，总交易额为 681,171.93 美元。出售后，首席执行官持有 288,976 股公司股票，价值约为 13,498,068.96 美元。这代表其持股减少了 4.80%。该交易的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士共出售了 30,108 股公司股票，价值为 1,302,370 美元。公司内部人士持有公司股票的 1.50%。</p>
<h2>机构投资者对 Terns Pharmaceuticals 的看法</h2>
<p>一些对冲基金最近增加或减少了在 TERN 的持股。瑞银资产管理（UBS AM）作为瑞银资产管理美洲有限公司的一个独立业务单位，在第四季度购买了 Terns Pharmaceuticals 的新股份，价值 25,000 美元。GAMMA Investing LLC 在第四季度将其在 Terns Pharmaceuticals 的持股增加了 762.4%。GAMMA Investing LLC 现在拥有 871 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 770 股。工程师门控管理 LP 在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 41,000 美元。iA 全球资产管理公司在第四季度购买了 Terns Pharmaceuticals 的新股份，价值 43,000 美元。最后，加拿大养老金计划投资委员会在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 46,000 美元。目前 98.26% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Terns Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗慢性肝病和其他严重疾病的口服小分子疗法。该公司的研发工作集中在新颖的作用机制上，旨在解决进展性肝病的根本原因，包括炎症、纤维化和代谢失调。通过推进可以口服给药的靶向化合物，Terns 旨在为患者提供比注射或生物疗法更方便和有效的治疗选择。</p>
<p>该公司的产品管线包含多个处于不同临床前和临床评估阶段的候选药物。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Terns Pharmaceuticals 更好</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBURZTeW1ib2w9VEVSTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
<p>在考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
<p>虽然 Terns Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TERN

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Oppenheimer 重申了对 Terns Pharmaceuticals（NASDAQ:TERN）的 “市场表现” 评级，目标价格为 58.00 美元，意味着潜在上涨幅度为 9.63%。该股票目前交易价格为 52.91 美元，分析师的平均评级为 “持有”。最近的内部交易包括首席执行官 Amy L. Burroughs 出售了 14,583 股。对冲基金持有该股票的 98.26%，反映出强烈的机构兴趣。Terns Pharmaceuticals 专注于开发慢性肝病和其他严重疾病的治疗方案</p>

<p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report)'s stock had its &#34;market perform&#34; rating reiterated by research analysts at Oppenheimer in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $58.00 price objective on the stock. Oppenheimer's price target would indicate a potential upside of 9.63% from the stock's current price.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）的股票在周一由 Oppenheimer 的研究分析师在一份发给客户和投资者的研究报告中重申了 “市场表现” 评级，Benzinga 报道。他们目前对该股票的目标价为 58.00 美元。Oppenheimer 的目标价意味着该股票当前价格有 9.63% 的潜在上涨空间。</p>
</div><p>Get <strong>Terns Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Terns Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of other analysts have also recently commented on TERN. BMO Capital Markets cut Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, March 26th. Wall Street Zen lowered shares of Terns Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, March 21st. Mizuho set a $53.00 price objective on shares of Terns Pharmaceuticals in a report on Friday, March 27th. William Blair lowered shares of Terns Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, April 7th. Finally, Barclays restated an &#34;equal weight&#34; rating and issued a $53.00 price objective (down from $56.00) on shares of Terns Pharmaceuticals in a report on Monday, March 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of &#34;Hold&#34; and a consensus target price of $55.14.</p>
<div class="lb-trans"><p>其他一些分析师也最近对 TERN 发表了评论。BMO 资本市场在 3 月 26 日的研究报告中将 Terns Pharmaceuticals 的评级从 “强力买入” 下调至 “持有”。华尔街 Zen 在 3 月 21 日的报告中将 Terns Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。瑞穗证券在 3 月 27 日的报告中对 Terns Pharmaceuticals 的股票设定了 53.00 美元的目标价。威廉·布莱尔在 4 月 7 日的报告中将 Terns Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。最后，巴克莱在 3 月 30 日的报告中重申了 “等权重” 评级，并对 Terns Pharmaceuticals 的股票设定了 53.00 美元的目标价（低于 56.00 美元）。一位投资分析师对该股票给予了强力买入评级，三位给予了买入评级，十位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，共识目标价为 55.14 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Terns Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Terns Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Terns Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 股票表现</h2>
</div><p>Shares of TERN traded up $0.02 during mid-day trading on Monday, reaching $52.91. The company had a trading volume of 747,846 shares, compared to its average volume of 4,899,822. The firm has a 50-day moving average price of $47.82 and a 200 day moving average price of $35.70. Terns Pharmaceuticals has a 52 week low of $2.65 and a 52 week high of $53.19. The company has a market capitalization of $6.11 billion, a price-to-earnings ratio of -51.36 and a beta of -0.37.</p>
<div class="lb-trans"><p>周一中午交易时，TERN 的股票上涨 0.02 美元，达到 52.91 美元。该公司的交易量为 747,846 股，而其平均交易量为 4,899,822 股。该公司的 50 日移动平均价格为 47.82 美元，200 日移动平均价格为 35.70 美元。Terns Pharmaceuticals 的 52 周最低价为 2.65 美元，52 周最高价为 53.19 美元。该公司的市值为 61.1 亿美元，市盈率为-51.36，贝塔值为-0.37。</p>
</div><p>Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last issued its quarterly earnings results on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, research analysts forecast that Terns Pharmaceuticals will post -1.07 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals（纳斯达克代码：TERN - 获取免费报告）最近在 3 月 30 日发布了季度财报。该公司报告每股收益（EPS）为-0.24 美元，超出分析师的共识预期（-0.30 美元）0.06 美元。整体来看，研究分析师预测 Terns Pharmaceuticals 在当前财政年度将发布-1.07 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 942 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the sale, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. The trade was a 0.88% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, CEO Amy L. Burroughs sold 14,583 shares of the business's stock in a transaction on Monday, March 16th. The shares were sold at an average price of $46.71, for a total transaction of $681,171.93. Following the sale, the chief executive officer owned 288,976 shares of the company's stock, valued at approximately $13,498,068.96. This represents a 4.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 30,108 shares of company stock valued at $1,302,370. Company insiders own 1.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Terns Pharmaceuticals 的新闻中，内部人士 Emil Kuriakose 在 4 月 1 日的交易中出售了 942 股该公司的股票。这些股票的平均售价为 52.75 美元，总交易额为 49,690.50 美元。交易完成后，该内部人士直接持有 105,673 股公司股票，价值约为 5,574,250.75 美元。此次交易使其持股减少了 0.88%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接访问。此外，首席执行官 Amy L. Burroughs 在 3 月 16 日的交易中出售了 14,583 股该公司的股票。这些股票的平均售价为 46.71 美元，总交易额为 681,171.93 美元。出售后，首席执行官持有 288,976 股公司股票，价值约为 13,498,068.96 美元。这代表其持股减少了 4.80%。该交易的披露信息可在 SEC 备案中找到。在过去一个季度，内部人士共出售了 30,108 股公司股票，价值为 1,302,370 美元。公司内部人士持有公司股票的 1.50%。</p>
</div><h2>Institutional Investors Weigh In On Terns Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Terns Pharmaceuticals 的看法</h2>
</div><p>A number of hedge funds have recently added to or reduced their stakes in TERN. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in Terns Pharmaceuticals during the 4th quarter valued at $25,000. GAMMA Investing LLC raised its stake in Terns Pharmaceuticals by 762.4% during the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company's stock valued at $35,000 after buying an additional 770 shares during the last quarter. Engineers Gate Manager LP purchased a new stake in Terns Pharmaceuticals during the 2nd quarter valued at $41,000. iA Global Asset Management Inc. bought a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at $43,000. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Terns Pharmaceuticals during the 2nd quarter valued at $46,000. 98.26% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金最近增加或减少了在 TERN 的持股。瑞银资产管理（UBS AM）作为瑞银资产管理美洲有限公司的一个独立业务单位，在第四季度购买了 Terns Pharmaceuticals 的新股份，价值 25,000 美元。GAMMA Investing LLC 在第四季度将其在 Terns Pharmaceuticals 的持股增加了 762.4%。GAMMA Investing LLC 现在拥有 871 股该公司的股票，价值 35,000 美元，此前在上个季度又购买了 770 股。工程师门控管理 LP 在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 41,000 美元。iA 全球资产管理公司在第四季度购买了 Terns Pharmaceuticals 的新股份，价值 43,000 美元。最后，加拿大养老金计划投资委员会在第二季度购买了 Terns Pharmaceuticals 的新股份，价值 46,000 美元。目前 98.26% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Terns Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Terns Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.</p>
<div class="lb-trans"><p>Terns Pharmaceuticals, Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗慢性肝病和其他严重疾病的口服小分子疗法。该公司的研发工作集中在新颖的作用机制上，旨在解决进展性肝病的根本原因，包括炎症、纤维化和代谢失调。通过推进可以口服给药的靶向化合物，Terns 旨在为患者提供比注射或生物疗法更方便和有效的治疗选择。</p>
</div><p>The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.</p>
<div class="lb-trans"><p>该公司的产品管线包含多个处于不同临床前和临床评估阶段的候选药物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Terns Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Terns Pharmaceuticals 更好</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEVSTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TERN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Terns Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Terns Pharmaceuticals 吗？</h2>
</div><p>Before you consider Terns Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Terns Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Terns Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Terns Pharmaceuticals 并不在名单上。</p>
</div><p>While Terns Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Terns Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Terns Pharmaceuticals (NASDAQ:TERN) Earns Market Perform Rating from Oppenheimer

Market Beat

Terns Pharmaceuticals

Terns Pharmaceuticals（纳斯达克代码：TERN）被 Oppenheimer 评为市场表现评级